I heard that a major international pharmaceutical company plans to acquire an innovative drug company for 20 billion USD, and the story behind it is quite worth paying attention to.

The targeted company has a drug called PanRas, which is currently the most promising candidate for pancreatic cancer treatment. To be honest, pancreatic cancer is almost an incurable disease so far, with no effective medicine. Because of this, some patients in China are purchasing this raw material drug, which is not yet on the market, at a monthly price of 120,000 RMB, enough to show how desperate the patients are.

But the problem is also obvious—this drug is ridiculously expensive. The synthesis process alone requires at least 25 steps, with costs frighteningly high. Once it is truly commercialized, the price will definitely be astronomical, starting at several million USD. Such a price is simply unaffordable for ordinary patients.

However, a turning point has arrived. Many domestic research teams are also making vigorous efforts, whether in the route of molecular glue or small molecule drugs, everyone is pushing forward intensively. Breakthrough days should not be far away. Once domestic companies succeed in R&D, the cost advantage will be very obvious, and the drug price will definitely be several times cheaper.

For pancreatic cancer patients, this is truly a glimmer of hope.